Access to Private Mushroom Deal

And even if you meet the criteria... getting access to quality private deals has proven difficult even for seasoned investors.

It’s tough to get invited to participate in the early funding rounds of companies that are done at low valuations.

You truly need to be plugged in and connected in the sectors you want to do private deals in.

I’m not talking about crowdsourcing or crowdfunding... or deals that anyone can participate in and find.

I’m talking about investing in private companies just before they go public...

Or in private placements in already public companies where you can get a discount to market and leverage in the form of warrants.

It's these kinds of private deals that I’ve used to build the bulk of my net worth. And my members have participated in them right alongside me.

We’ve done them across multiple sectors, including gold, copper, biotech, and cannabis.

That last one is special.

Because every so often in the market you get a new sector that forms and the profit wave is hard to believe. Getting ahead of one of those waves changes lives.

My readers and I made hundreds and hundreds of percent from 2015 to 2018 on the pot stock runup.

We financed companies like The Green Organic Dutchman at $1.65 ahead of it going public and running to over $10.00... and Emblem Corp at $0.75 before listing and trading over $3.50.

Now, a mushroom swell is developing. You’ve probably read something about it.

This month, the first research was published in the New England Journal of Medicine that compared psychedelic mushrooms to Lexapro (escitalopram) for their antidepressant properties. The mushrooms reduced the symptoms of depression at least as well as Lexapro.

People, naturally, have known this for years.

But now, with the advent of microdosing, you don’t have to “trip your balls off” every time you take psilocybin.

It’s catching on fast. Rumors are that magic mushroom microdosing is already generating tens of millions of dollars in sales per month on the, shall we say, gray market.
                      
And bills have already been floated in several states to either decriminalize or legalize psilocybin in its medical form.

Are we going to get a run like we saw with cannabis stocks? We’ll see.

The “functional mushroom” market is forecast to grow at an 8.04% annual clip to $34.3 billion by 2024. That includes non-psychedelic mushrooms for medicines and supplements.

The psychedelic drug market is expected to grow even faster, albeit with a smaller piece of the pie. Projections are for 16.3% annual growth in the space from 2020 to 2027, during which it will grow from a $2 billion to a $7 billion sector.

Scientific American says “The Mycelium Revolution Is Upon Us.” They are referring specifically to the fungus mushrooms are made of, and saying it can be used to replace everything from styrofoam to meat.

For example, Adidas is working on a pair of mushroom leather sneakers.

Medical research is also in its very early stages, just like it was in the early days of the cannabis boom.

Am I willing to make a few speculations in the sector? You bet.

We will be doing that very soon via a new private deal for members of the Hodge Family Office.

You must be a member to participate.

I will be sending out info to members over the next few days and the round will close quickly. It will then begin trading via a reverse takeover.

Don’t wait if you want to get in on this sector.

Claim one of the remaining 250 spots today.

Call it like you see it, 
 

Nick Hodge,
Publisher, Resource Stock Digest
 

Nick Hodge is the co-owner and publisher of Resource Stock Digest. He's also the founder and editor of Hodge Family Office, Family Office Advantage, and Foundational Profits . He specializes in private placements and speculations in early stage ventures, and has raised tens of millions of dollars of investment capital for resource, energy, cannabis, and medical technology companies. Co-author of two best-selling investment books, including Energy for Dummies, his insights have been shared on news programs and in magazines and newspapers around the world.